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and untreatable, it may preclude them from seeking treatment. Third, MHLt posits 
that KABs collectively determine HSB unidirectionally. A bidirectional relationship 
may be more appropriate because patient behavior and human decision-making 
are fluid and constantly changing. In addition, this bidirectional relationship allows 
for a period of assessment necessary for patients to weigh their KABs against the 
current situation. Lastly, another needed component is resource availability (e.g., 
access to care and insurance status). In conclusion, as the first theory to conceptual-
ize literacy regarding mental health, the MHLt laid the foundation for exploring the 
relationship between KABs and HSB however, several improvements and additions 
to the theory may advance this body of work.
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The expiry dates mentioned on the medicines are considered inviolable by the 
patients. Given by the manufacturer and approved by the highest regulatory agen-
cies of a country, expiry date is considered as the ultimate safeguard to ensure the 
safety of the medicine being used by the patients. Exaggerated expiration dates 
pose economic burden on the health care system of a country, the effect being 
more significant in the underdeveloped and developing economies. In developed 
countries these issues have been addressed by using pharmacoeconomic tools like 
a. Cost- minimization analysis b. Cost- effective analysis c. Cost- utility analysis d. 
Cost- benefit analysis. The outcome of the studies conducted under the Shelf Life 
Extension Program by FDA clearly indicate that pre-occupation with the safety 
issues has resulted in all stake-holders being too conservative about the expiry 
dates. This results in the wasteful disposal of the drugs which are still therapeuti-
cally effective after their labelled expiry dates. This article discusses the general 
societal notions about the expiry dates of the drugs, the procedures being generally 
followed by pharmaceutical industries to give the expiration dates to the drugs, 
cases where the expiry dates have been extended by the regulatory agencies them-
selves and a testing program that started as an Air Force initiative in collaboration 
with FDA and saved American taxpayers millions of dollars. The article also recom-
mends the scientific course that may be taken towards a more pragmatic approach 
towards the expiry date labelling.
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Objectives: At present, the digital divide is generally considered a problem of 
access. This perspective is perpetuated by several assumptions regarding the 
availability, usability, and content of current health information and technological 
communications (ICT) promoting chronic care management. These biases serve to 
limit benefits of health technology innovation among the medically underserved 
or at-risk patient populations. Most prominent, the myths of ready access and sus-
tained engagement are presented - both of which differentially expose already 
vulnerable groups to fewer technological advances to improve patient care readily 
available to other groups in addition to poorer quality information to base medi-
cal decisions upon, thus reinforcing disengagement and potentially widening the 
divide. MethOds: By drawing on a range of literatures, including health com-
munications, medical informatics, social determinants of health, health behav-
ior and promotion, the purpose of this work is to deconstruct the divide, describe 
its importance and impact in health care settings, in an effort to improve under-
standing of its role in medication adherence and patient engagement in order to 
inform tailored intervention development. Results: Specifically, this conceptual 
work describes elements and challenges assumptions driving the divide in order 
to: expand understanding of the digital divide in practice, recognize important 
patient groups are being negatively impacted, and increase awareness of eHealth 
literacy and efficacy that may directly impact adherence and patient engagement. 
Examples of patient-centered technology tools are provided, such as the Personal 
Health Record (PHR), illustrating the potential for reducing as well as increasing the 
digital divide; if features of the divide are not considered when developing techno-
logically-based behavioral interventions, those relying on health ICT may serve to 
amplify inequalities in health and health care. cOnclusiOns: Conclusions elu-
cidating the elements upon which patient-centered interventions may be tailored 
appropriately are offered, providing suggestions to inform both population-based 
as well as individual-based health management strategies.
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intROductiOn: Judicialization of health is the terminology that refers to the sig-
nificant increase in lawsuits (legal queries) aiming to provide drugs and medical 
treatments. In this sense, since the role of the Judiciary is considered essential to 
confirm the social and constitutional rights to health, the legal sentences provoke 
a point of tension for policy-makers and for the government, compelled to ensure 
provisions that are in conflict with the budget established and policies for the 
health care sector. Objectives: To describe the importance of Health Technology 
Assessment (HTA) in helping to orientate judges, patients, policy-makers and other 
legal actors in lawsuits. MethOds: Analytical paper. Results: The evolution of 
medicine requires programmatic bias about the right to health, as always there will 
be new discoveries, new procedures, new diseases or the return of once eradicated 
diseases. Studies on efficacy, safety, effectiveness and cost-effectiveness are the 
main components of the Health Technology Assessment (HTA) field, which can be 
the importance of POLs, to propose a method to measure a POL’s influence, and to 
examine the possible roles of POLs.
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Objective: The life sciences and health technology (LSHT) sector is one of the key 
knowledge based area in Quebec. It provides for economic growth, wealth creation 
and quality of life improvement. The LSHT sector has been experiencing important 
changes of its R&D model over the past 5 years, hense modifying resources alloca-
tion. The objective of this analysis was to describe the LSHT in Quebec, look at its 
recent evolution and identify key elements of success contributing to grow this 
sector. MethOds: Information, gathered from the Quebec ministry of finance and 
economy, Quebec Institute of Statistics, Statistics Canada, Montréal International, 
US Bureau of Labor Statistics, Eurostat and Europe Innova, was used to develop a 
comparative analysis of the LSHT sector concerning wealth creation and economic 
growth for selected LSHT sub-sector in selected Canadian provinces, US states and 
European regions. The following information was gathered for the analysis: public 
and private employment and salaries (direct and indirect), gross domestic product 
(GDP), concentration of employment. Results: The analysis shows that the LSHT 
sector accounts for 1.5% of Quebec GDP and that employment in this sector gener-
ates more value (+70%) when compared to all the other economic sectors taken 
together. The comparative analysis, based on 35 regions in Europe, United States 
and Canada, shows that Quebec is one of the 3 regions with a diversified LSHT sec-
tor while other regions have specialized in one subsector (biotechnology, medical 
technology, pharma). The results show also that only 22% of regions grew between 
2008-2012. cOnclusiOn: This analysis suggests that the growth of LSHT cannot 
only be explained by the diversity of the subsector activities. The presence of large 
research and health centers as well as collaborative approach could explain the 
success for that growth. Further analysis would be required to measure the impact 
of each of these factors.
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Objectives: Pharmaceutical stakeholders in Central Eastern Europe (CEE) often 
refer to international evidence from other jurisdictions to express the benefits of 
innovative medicines in cost savings or productivity gain. One of the most fre-
quently cited statements argues that increased expenditure on innovative medi-
cines may be offset by reduced hospital stay or avoided complications. Another 
popular argument is to express the value of modern medicines with the potential 
link between life expectancy and GDP growth. The aim of this research is to evalu-
ate the transferability of the most frequently referred international case studies 
to CEE. MethOds: Detailed literature review and appraisal of the transferability 
of these approaches to CEE. Results: CEE countries differ in several important 
aspects from high income countries: the overall health status of the population 
is worse; the price level of health care services is lower, mainly due to lower man-
power costs. On the contrary there is no significant difference in the price level of 
innovative medicines compared to high income countries. As the relative cost of 
hospitalisation is lower than cost of medicines in CEE countries, the cost saving 
potential from avoided hospitalisation and complications is more limited. As an 
average person in CEE countries lives longer than the retirement age, it is difficult 
to judge how additional life-years of inactive populations can increase productivity 
gain and consequently how it may contribute to GDP growth. As increased longev-
ity increases health expenditure, the major benefit of innovative medicines can 
be health gain in CEE. cOnclusiOns: The expectation to control overall health 
expenditure by extensive use of innovative drugs is unrealistic in the CEE region. 
Transferability of real world evidence on the benefits of innovative medicines from 
high income countries to lower income countries is limited.
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Mental illness (MI) is a national problem and over 60% of people who suffer from 
MI do not receive treatment. Understanding factors that may impact treatment 
seeking is important in developing effective intervention programs. Mental Health 
Literacy theory (MHLt) purports that one’s knowledge, attitudes and beliefs (KABs) 
about the following MI domains: 1)causes; 2)recognition; 3)how to seek information; 
and 4)sources of help can predict their help-seeking behaviors (HSB). The purpose 
of this paper is to critically evaluate the predictors and directionality of MHLt. This 
systematic analysis resulted in meaningful alterations to the theory based upon the 
need for the individual’s perspective on MI. MHLt conceptualizes the level of one’s 
literacy from a ‘top down’ approach. If a patient’s KABs are contrary to those of the 
professional community, then the patient is deemed to have low MHL. This approach 
minimizes patients’ experiences and beliefs, and may place the views of the pro-
fessional at odds with that of the patient resulting in disillusionment and distrust 
of the health care system. Second, MHLt neglects the role of prevention and self-
management, which is problematic because if a patient views MI as unpreventable 
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lenges and opportunities. Results: Only 22%-27% of payers and providers believe 
that personalized medicine is a “very important” strategic goal versus ~50% of large 
biopharma manufacturers. Although 47%-52% of all stakeholders have integrated 
staff with area expertise, fewer than 20% have developed a centralized focus on 
personalized medicine and only 8%-20% believe they have tools to evaluate its suc-
cess. Decision maker perspectives ranged broadly on its key benefits but included 
improved and more predictable outcomes and cost efficiencies. Approximately 30% 
of all stakeholders believe that personalized medicines will continue to receive pre-
mium pricing to justify ROI for this business approach. cOnclusiOns: Although 
most stakeholders see value in personalized medicines, they struggle with practical 
implementation and need actionable strategies to characterize the value and impact 
of these technologies. The survey suggests that limited emphasis on infrastructure 
development and methods, heterogeneous value assessment, and misalignment 
of incentives remain key challenges to enabling care and economic efficiencies 
promised by this evolving treatment paradigm.
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Objectives: Reliable price data could enable consumers to choose providers that 
offer better value than others, eventually leading to market-level gains in quality 
and efficiency. The objective of this study is to predict price-to-charge ratios (PCRs) 
for community hospital stays on the basis of charge data and information about 
individual stays, hospitals, market areas, and states. MethOds: We used 2006 
Healthcare Cost and Utilization Project State Inpatient Databases from California, 
Florida, Massachusetts, Nevada, New Jersey, Virginia, West Virginia and Wisconsin. 
We predicted PCRs for major payer categories for over 1,000 community hospitals 
as a function of state, market, hospital, and patient characteristics using expo-
nential conditional mean models with a log link and gamma-distributed errors. 
The unit of analysis was the hospital. We used a two-stage iterative estimation in 
which equations are estimated individually and the errors saved. In the next step, 
each payer equation is estimated a second time with the first-stage errors of the 
other payer equations as new independent variables. We assessed goodness of fit 
through model characteristics and by assessing the match of actual and predicted 
PCRs. Results: Average demographic characteristics were significant predictors of 
PCRs for Medicare and Private insurance, but not for Medicaid or Self-Pay. Hospital 
characteristics were related to every PCR category. Critical-access hospitals and 
teaching hospitals were associated with significantly greater PCRs for Medicare, 
Medicaid, and Private insurance holders. Greater numbers of Medicare and Medicaid 
discharges were associated with significantly lower PCRs. Higher PCRs were most 
often associated with worse economic conditions and greater state generosity in 
Medicaid eligibility and spending. cOnclusiOns: Inpatient encounter prices paid 
by Medicare, Medicaid, and private insurance can be estimated with acceptable 
accuracy for community hospital stays. Stays funded by other insurance types or 
by patients were harder to predict and simultaneously have almost no correlation 
with PCRs.
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bAckgROund: Over the last decade, evidence-based assessment of food and 
nutritional products has substantially accelerated, in a fast-moving market and 
regulatory environment. Specific evidence synthesis, epidemiological and phar-
maco-economic tools have been increasingly required, developed and used for 
HTA and public health decision support. Objectives: This presentation high-
lights through case studies the specific needs, tools and challenges arising from 
health economic evaluations of nutritional products. MethOds: To first set the 
scene of nutritional product assessment, the regulatory and HTA systems and 
guidelines in both Europe and the US will be described and potential differences 
with drugs or devices highlighted. Through a series of illustrative but representa-
tive case studies covering both health claims and medical nutrition, the specific 
data needs and statistical methods to analyse them will reviewed and discussed. 
Data and methods gaps will be highlighted and consequences on the market 
access strategies and tactics will be discussed. Results: Nutritional products 
would typically target a wider and heterogeneous group of population than 
common drugs. Furthermore, control of food/compound exposure and effect in 
observational and clinical studies is more challenging resulting in larger studies 
and requiring more stringent tracking of compliance. Data analysis then requires 
refined statistical models such as hierarchical models able to handle population 
variability. Safety issues are also expected to be minimal to make benefit/risk 
evaluation acceptable by regulators, so that risk studies and risk management 
tactics should be designed accordingly. Finally, pricing and reimbursement depend 
even more than drugs on how the compound is positioned and for which target 
population. CONCLUSION Standard tools for evidence synthesis and pharmaco-
economic tools applied to nutritional products market access need to be stretched 
to their best to handle the higher population heterogeneity and numerous market 
access options.
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treated as the “intelligence” of the incorporation process procedures in the pub-
lic health system. Efficacy refers to the benefic effect in experimental conditions; 
effectiveness mentions the benefic effect operating under the system’s conditions, 
i.e. the action field; and cost-effectiveness refers to the objective when confronted 
with the costs involved in bringing the procedure into the system. cOnclusiOns: 
The evidence researched by the HTA area, and not individual medical decisions or 
judicial sentences, should lead the policies on public health. The need to study the 
process of judicialization of health through HTA is evident.
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The Association of Southeast Asian Nations or ASEAN consists of ten member 
states. In 2007, the ASEAN leaders determined that the ASEAN Community will be 
established by 2015. The ASEAN Community will become a region with free move-
ment of goods, services, investment, skilled labor, and freer flow of capital. Since 
the trend in medical tourism continues growing worldwide, countries in ASEAN 
are strongly encouraging medical tourism as well. In particular, the Thai govern-
ment is promoting Thailand as a major medical hub in Asia as part of an effort to 
expand and diversify exports. Thailand aims to make itself the leading medical hub 
and the center for medical tourism. In this paper, the establishment of the ASEAN 
Community together with the transformation of Thailand as a medical hub is evalu-
ated. There are some concerns for both Thai and international patients who will 
receive Thai health care services. The increased number of international patients 
from becoming a medical hub along with the forming of the ASEAN Community 
would affect pharmaceutical costs in Thailand and put extra strain on its health 
care system. In addition to the escalated number of foreign patients, the shortage of 
health care professionals and the problem of their distribution in the country would 
be exacerbated. Last, this paper discusses proposed alternatives for the issue. One 
alternative solution that might diminish the effect of rising pharmaceutical costs to 
Thai patients is that the Thai government needs to negotiate with pharmaceutical 
firms producing brand-name medicine on behalf of Thai public hospitals. To reduce 
the shortage of the health care professionals in Thailand, the restrictions on foreign 
health care professionals should be loosened.
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Objectives: There has been increase in the number of multi-criteria decision analy-
sis (MCDA) applications in health care since 1990s but there is still confusion among 
potential users regarding their appropriate use and this paper reports on an expert 
MCDA meeting organised to address these issues. MethOds: An expert meeting 
was held in 2013 in UK with 21 representatives from a variety of governmental, 
academic and pharmaceutical institutes, which had the objective to discuss the 
role, options and limitations of MCDA in health. Results: The key messages and 
good practice recommendations developed by the participants of the expert meeting 
are as follows: a) Problem structuring is key: it is recommended that enough time is 
allocated to understand and specify the decision problem under consideration, b) 
Numerical MCDA modelling is not always necessary: deliberative discourse with the 
performance matrix as a starting point is sufficient in some situations rather than 
numerical MCDA models, c) Variety of weighting and scoring techniques: There are 
a number of different methods to estimate the value scores and to elicit the weights 
but not all scoring methods and weighting techniques are suitable for every MCDA 
method, d) Visualisation/transparency is important: For the decision makers to have 
confidence in the MCDA model, the model outputs need to be adequately visualised 
and the model needs to be transparent, e) Uncertainty modelling: appropriate care 
needs to be taken in performing uncertainty analysis cOnclusiOns: MCDA has 
already been used and is well suited to support a broad range of health care decision 
problems but there is a need to develop a framework to select the appropriate MCDA 
technique for specific health care decisions. Future work is underway to develop 
the guidelines for choosing the most appropriate MCDA method to be applied for a 
given health care decision problem.
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Objectives: As the US health care system drives toward population-level goals 
for efficiency and effectiveness, demand persists for more personal care at the 
patient-level. Personalized medicine is an emerging business model that harnesses 
genomics and biotechnology aimed at tailoring therapies and interventions to indi-
vidual patient characteristics. Market stakeholders universally acknowledge the 
tectonic shift away from the historic blockbuster drug model to a more targeted 
model. To evaluate current insights and challenges, we surveyed key stakeholders 
and decisions makers across the health care industry. MethOds: We conducted a 
survey of approximately 300 biopharma executives, payers, and providers in the US 
and EU to gain insight into their needs, perceptions, and readiness to shift toward 
a more robust personalized medicine approach. This original research is aimed 
to characterize current status of infrastructure, preparedness, adoption and value 
assessment around personalized medicine development and highlight key chal-
